arrow
B

Bertrand Tombal

Université catholique de Louvain
H指数:78
被引数:3.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Testosterone monitoring and supplementation in patients with intermediate- or high-risk prostate cancer treated with 6–36 months of androgen deprivation therapy and radiotherapy: a systematic literature review

对接受6–36个月雄激素剥夺疗法和放射治疗的具有中危或高危前列腺癌患者的睾酮监测和补充:一项系统文献综述

2026-09-120
PRE
Alkaline Phosphatase and Prostate-specific Antigen Response in Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide Alone or in Combination with Radium-223: Ad Hoc Analysis of the PEACE-3 Consortium Trial

碱性磷酸酶和前列腺特异性抗原在转移性去势抵抗性前列腺癌中,经恩扎卢胺单药或联合镭-223治疗后的反应:PEACE-3联盟试验的临时分析

2026-08-280
OAAI
Real-world treatment patterns and clinical outcomes in patients with non-muscle invasive bladder cancer: a nationwide evaluation

非肌肉浸润性膀胱癌患者的真实世界治疗模式与临床结局:一项全国性评估

2026-08-130
OA
Radiomics and Image-based Artificial Intelligence for Predicting Recurrence and Survival After Surgery in Localized Renal Cell Carcinoma: An APPRAISE-AI Systematic Review and Meta-analysis

放射组学及基于图像的人工智能在预测局限性肾细胞癌术后复发和生存中的应用:一项APPRAISE-AI系统评价和荟萃分析

2026-01-120
PRE
Accelerating cancer treatment optimisation: A multistakeholder roadmap from the Cancer Medicines Forum

加速癌症治疗优化:癌症药物论坛的多利益相关方路线图

2026-01-010
OAAI
Chromosomal instability in circulating tumor cells and cabazitaxel resistance in metastatic castration-resistant prostate cancer

循环肿瘤细胞中的染色体不稳定性与转移性去势抵抗性前列腺癌中的卡巴他赛耐药性

2025-12-220
OA
Early favorable prostate-specific antigen response prediction in metastatic hormone sensitive prostate cancer

早期对转移性激素敏感型前列腺癌的 prostate-specific antigen (PSA) 阳性反应预测

2025-12-170
OAAI
A roadmap for future clinical research in advanced prostate cancer: Findings from the Advanced Prostate Cancer Consensus Conference (APCCC) 2024

未来晚期前列腺癌临床研究的路线图:2024年晚期前列腺癌共识会议(APCCC)的研究结果

2025-11-210
PRE
Radiotherapy plus Long-term Adjuvant Androgen Deprivation with a Luteinizing Hormone–releasing Hormone Antagonist Versus Agonist in Patients with Very High-risk Localized or Locally Advanced Prostate Cancer: The EORTC GUCG-1414 Phase 3 Randomized Trial

放疗联合长效辅助雄激素剥夺(使用促黄体生成素释放激素拮抗剂与激动剂对比)在极高风险局限性或局部晚期前列腺癌患者中的应用:EORTC GUCG-1414 III期随机试验

2025-11-070
OAAI
Comparative Survival in Metastatic Hormone-sensitive Prostate Cancer by Volume of Disease and Timing of Metastasis: A Living Network Meta-analysis

比较性生存分析:激素敏感性转移性前列腺癌按疾病体积和转移时间划分——一项动态网络Meta分析

2025-11-040
PRE
Age-related Efficacy and Safety of Darolutamide Plus Androgen-deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-sensitive Prostate Cancer: A Subgroup Analysis of the Phase 3 ARASENS Trial

年龄相关的达罗他胺联合雄激素剥夺疗法和多西他赛在转移性激素敏感前列腺癌患者中的疗效与安全性:一项ARASENS III期试验的亚组分析

2025-11-040
OAAI
A plain language summary of the EORTC 1333/PEACE-3 study of enzalutamide alone vs enzalutamide plus radium-223 in patients with metastatic castrationresistant prostate cancer (mCRPC) and bone metastases

EORTC 1333/PEACE-3研究的通俗摘要:恩扎卢胺单药与恩扎卢胺联合镭-223治疗伴有骨转移的转移性去势抵抗性前列腺癌(mCRPC)患者的比较研究

2025-11-010
PRE
Adjusting for abiraterone-prednisone cross-over in de novo metastatic castration-sensitive prostate cancer: a post-hoc analysis of the PEACE-1 trial

调整阿比特龙-泼尼松交叉对原发转移性去势敏感前列腺癌的影响:PEACE-1试验的事后分析

2025-09-270
PRE